Gaois

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

5 results

  1. SOCIAL QUESTIONS|health|pharmaceutical industry · SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine · PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology

    #634590

    IATE #1686508
    vacsaín athchuingreach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    rekombinanter Impfstoff | Impfstoff auf der Grundlage rekombinierender DNA
    de
    recombinant vaccine
    en
    Definition vaccine developed using recombinant technologies Reference "COM-Terminology Coordination, based on: Yadav T, Srivastava N, Mishra G, et al., 'Recombinant vaccines for COVID-19' (9.3.2021), Human Vaccines & Immunotherapeutics 2020;16(12):2905-2912, doi:10.1080/21645515.2020.1820808"
    vaccin recombinant | vaccin basé sur la recombinaison d'ADN
    fr
    Definition vaccin obtenu par génie génétique Reference "Vidal EurekaSanté. Lexique médical. Vaccin http://www.eurekasante.fr/lexique-medical/V.html [20.9.2011]"
  2. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine · SOCIAL QUESTIONS|health|pharmaceutical industry · PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology

    #685622

    IATE #3590043
    vacsaín veicteora víreasaigh Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    viraler Vektorimpfstoff
    de
    viral vector vaccine | viral vector-based vaccine | live recombinant viral vectored vaccine | virus vector vaccine | virus vector vaccines
    en
    Definition vaccine consisting of a live virus (the vector) that expresses a heterologous antigen(s) Reference "COM-Terminology Coordination: European Medicines Agency. Committee for Medicinal Product for Human Use (CHMP) 'Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines' (9.3.2021). 24 June 2010 EMA/CHMP/VWP/141697/2009"
    Comment Heterologous vector: When the target species of the vaccine is not one of the natural hosts for the vector, the vector is classified as a heterologous vector.
    vaccin à vecteur viral | vaccin à base de vecteur viral | vaccin vectoriel
    fr
    Definition "vaccin qui consiste à combiner le virus à combattre avec un autre virus atténué ou inoffensif utilisé comme véhicule (vecteur viral), permettant de délivrer les antigènes directement dans les compartiments du système immunitaire susceptibles d’induire une réponse mémoire protectrice" Reference "COM-FR, d'après:- MSN Actualité, Article issu du Journal Le Soir (29 avril 2020), Vaccins anti-covid: une équation à plusieurs inconnues (1.7.2020)- Institut Pasteur, Communiqué de presse du 19 mars 2020 > Covid-19 : le CEPI finance le développement d’un vaccin contre SARS-CoV-2, projet porté par le consortium de l’Institut Pasteur, de Themis et de l’université de Pittsburgh (1.7.2020)"
  3. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #642983

    IATE #3510246
    vacsaín beoveicteora athchuingreach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    rekombinanter Lebendimpfstoff
    de
    recombinant live vector vaccine
    en
    Definition preparations of one or more types of live bacteria or viruses into which one or more DNA/RNA sequences have been inserted Reference "COM-Terminology Coordination, based on: European Medicines Agency (EMA). COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP). 'GUIDELINE ON LIVE RECOMBINANT VECTOR VACCINES FOR VETERINARY USE' (9.3.2021). EMEA/CVMP/004/04-FINAL"
    Comment Recombinant live vector vaccines are expected to be attenuated and genetically defined live vaccines, which have defined, non-reverting mutations or deletions.
    vaccin vivant à vecteur recombinant | vaccin vivant recombinant
    fr
  4. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #664943

    IATE #3593154
    vacsaín phróitéine athchuingreach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    vacsaín fo-aonaid phróitéine athchuingreach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    recombinant protein subunit vaccine | recombinant protein vaccine | recombinant subunit | recombinant protein-based vaccine
    en
    Definition "type of protein subunit vaccine that is formulated using defined protein antigens that can be produced in heterologous expression systems" Reference "COM-Terminology Coordination, based on: Wang M, Jiang S, Wang Y. 'Recent advances in the production of recombinant subunit vaccines in Pichia pastoris' (9.3.2021). Bioengineered. 2016;7(3):155-165. doi:10.1080/21655979.2016.1191707"
  5. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #665658

    IATE #3599598
    vacsaín nanacháithníní spícephróitéine athchuingreach SARS-CoV-2 Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    SARS-CoV-2 recombinant spike protein nanoparticle vaccine
    en
    Definition recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant Reference "Cheryl Keech, M.D., Ph.D., Gary Albert, M.S., Iksung Cho, M.S., Andreana Robertson, M.S., Patricia Reed, B.S., Susan Neal, Joyce S. Plested, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark, B.S., Haixia Zhou, Ph.D., Gale Smith, Ph.D., Nita Patel, M.S., Matthew B. Frieman, Ph.D., Robert E. Haupt, M.S., James Logue, B.A., Marisa McGrath, B.A., Stuart Weston, Ph.D., Pedro A. Piedra, M.D., Chinar Desai, B.S., Kathleen Callahan, M.S., Maggie Lewis, M.S., Patricia Price-Abbott, M.S., Neil Formica, M.B., B.S., Vivek Shinde, M.D., Louis Fries, M.D., Jason D. Lickliter, M.B., B.S., Ph.D., Paul Griffin, M.D., Bethanie Wilkinson, Ph.D., and Gregory M. Glenn, M.D., 'Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine' (18.6.2021), New England Journal of Medicine 2020; 383:2320-2332"
    NVX-CoV2373
    mul